Amgen Inc. (NASDAQ:AMGN) Stock Holdings Raised by Compass Ion Advisors LLC

Compass Ion Advisors LLC lifted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 4.1% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,192 shares of the medical research company’s stock after purchasing an additional 204 shares during the period. Compass Ion Advisors LLC’s holdings in Amgen were worth $1,476,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Norges Bank acquired a new stake in Amgen during the fourth quarter worth about $1,556,912,000. International Assets Investment Management LLC bought a new stake in shares of Amgen in the 4th quarter worth approximately $4,589,900,000. Royal Bank of Canada boosted its position in Amgen by 14.8% during the 4th quarter. Royal Bank of Canada now owns 5,831,624 shares of the medical research company’s stock valued at $1,679,625,000 after purchasing an additional 751,947 shares during the period. Assenagon Asset Management S.A. grew its stake in Amgen by 486.6% during the 4th quarter. Assenagon Asset Management S.A. now owns 899,232 shares of the medical research company’s stock worth $258,997,000 after buying an additional 745,929 shares during the last quarter. Finally, abrdn plc increased its position in Amgen by 150.4% in the fourth quarter. abrdn plc now owns 1,043,609 shares of the medical research company’s stock worth $300,580,000 after buying an additional 626,810 shares during the period. Institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling

In other news, SVP Nancy A. Grygiel sold 2,117 shares of the company’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $313.09, for a total value of $662,811.53. Following the transaction, the senior vice president now owns 9,883 shares in the company, valued at approximately $3,094,268.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.69% of the company’s stock.

Amgen Trading Down 0.4 %

NASDAQ:AMGN opened at $312.45 on Monday. The stock has a fifty day simple moving average of $301.56 and a 200 day simple moving average of $292.30. The firm has a market capitalization of $167.61 billion, a price-to-earnings ratio of 44.64, a price-to-earnings-growth ratio of 2.82 and a beta of 0.58. Amgen Inc. has a 1-year low of $218.44 and a 1-year high of $329.72. The company has a quick ratio of 0.98, a current ratio of 1.42 and a debt-to-equity ratio of 11.96.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share for the quarter, topping the consensus estimate of $3.76 by $0.20. The business had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $7.45 billion. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The firm’s quarterly revenue was up 22.0% compared to the same quarter last year. During the same period last year, the firm posted $3.98 earnings per share. Sell-side analysts forecast that Amgen Inc. will post 19.47 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on AMGN shares. Argus boosted their price target on shares of Amgen from $300.00 to $340.00 and gave the company a “buy” rating in a report on Thursday. UBS Group raised their price target on shares of Amgen from $284.00 to $307.00 and gave the company a “neutral” rating in a research note on Friday, May 3rd. William Blair upgraded Amgen from a “market perform” rating to an “outperform” rating in a research report on Friday, May 3rd. Royal Bank of Canada increased their price target on Amgen from $328.00 to $332.00 and gave the stock an “outperform” rating in a research note on Friday, June 14th. Finally, Morgan Stanley upped their price objective on shares of Amgen from $271.00 to $310.00 and gave the stock an “equal weight” rating in a report on Friday, May 3rd. Ten investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $307.35.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.